In contrast, a recent review showed increased mortality with the use of tumor necrosis factor inhibitors (TNFi) in RA-ILD; therefore, TNFi may have lower priority in the treatment of RA-ILD [55,68]. Here, TNF is linked to interstitial lung disease.